Consensus Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Real-time Estimate Cboe BZX Other stock markets 12:25:14 2024-06-03 pm EDT			5-day change	1st Jan Change
242.8 ^USD	+2.83%		+8.68%	+4.88%

May. 19	Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	CI
May. 19	Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	CI

Evolution of the average Target Price on Madrigal Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c4aca77503704a0a9b.0YvtuK0CpHfx9SmRvFm_dNJSORQov4YbH0gTg_FKckg.vP3Zz55S8ia5nVqn6Wn1MJYEbydSyKsrQHthxMUSKzmT6bf26VbgPZyWcA~7a521ef17f9d12824e67c8ab5a7de895

Analyst Recommendations on Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing	May. 17	MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating	May. 10	MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating	May. 09	MT
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	Apr. 22	MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	Apr. 22	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing	Apr. 11	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing	Apr. 04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing	Apr. 04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing	Apr. 04	MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating	Mar. 20	MT
Madrigal commences $500 million public offering of common stock	Mar. 18	RE
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating	Mar. 15	MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating	Mar. 15	MT
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating	Mar. 15	MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating	Mar. 15	MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating	Mar. 15	MT
B. Riley Upgrades Madrigal Pharmaceuticals to Neutral From Sell After FDA Approval of Rezdiffra, Raises PT to $270 From $155	Mar. 15	MT
HC Wainwright Adjusts Madrigal Pharmaceuticals' Price Target to $405 From $275, Maintains Buy Rating	Mar. 12	MT
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $320 From $300, Maintains Outperform Rating	Mar. 01	MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Says Nearly All Stock Scenarios Point to Higher Likelihood of Downside; Adjusts PT to $155 From $204	Feb. 27	MT
B. Riley Downgrades Madrigal Pharmaceuticals to Sell From Neutral, Cuts Price Target to $155 From $204	Feb. 26	MT
Piper Sandler Adjusts Price Target on Madrigal Pharmaceuticals to $336 From $305, Maintains Overweight Rating	Jan. 24	MT
Jefferies Cuts Madrigal Pharmaceuticals Price Target to $321 From $340, Maintains Buy Rating	Jan. 18	MT
B. Riley Raises Madrigal Pharmaceuticals' PT to $204 From $154 on Increased Resmetirom Pricing Guidance, Keeps Neutral Rating	Jan. 17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

236.2 USD

Average target price

363.9 USD

Spread / Average Target

+54.07%

High Price Target

507 USD

Spread / Highest target

+114.68%

Low Price Target

150 USD

Spread / Lowest Target

-36.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Madrigal Pharmaceuticals, Inc.

B. Riley
UBS
BofA Securities
Evercore ISI
TD Cowen
Citigroup
JMP Securities
HC Wainwright
Oppenheimer
Piper Sandler
Jefferies & Co.
Canaccord Genuity
SVB Securities LLC
Goldman Sachs
BMO Capital
Chardan

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar